Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate – BioSpace
Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate BioSpace
In: PATENT NEWS
Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate BioSpace
In: PATENT NEWS
Novartis Asks SCOTUS to Deny Review of Gilenya Patent Decision · More from Bloomberg Law.
In: PATENT NEWS
17, 2021 /PRNewswire-PRWeb/ — In January 2016, the founding partners and 12 employees came together to form a new patent law firm with …
In: PATENT NEWS
Closing the Patenting Gender Gap Requires More Women Patent Attorneys | The Legal Intelligencer Law.com
In: PATENT NEWS
Nicole D. Galli has practiced IP law for nearly 30 years, most of that time concentrating her practice on technical disputes including patent infringement …
In: PATENT NEWS
Adamis Pharma Shares Fall Despite US Patent Covering Naloxone Yahoo Finance
In: PATENT NEWS
OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011 GlobeNewswire
In: PATENT NEWS
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that it has strengthened intellectual property rights for its …
In: PATENT NEWS
… strengthened intellectual property rights for its anti-interleukin-7 receptor (IL-7R) antagonist OSE-127/S95011 through the granting of a first patent by …
In: PATENT NEWS
(1) Whether the patent at issue, United States Patent 6,038,295, titled an … Patent Law, Subject Matter, General Overview, Utility Patents, Process …
Designed by Industrial Action
Copyright © 2025 OPUS IP Limited. All Rights Reserved
OPUS IP Limited: COMPANY & OTHER LEGAL INFORMATION